This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Circulation Heart Failure Transplant 
DAIC
FEBRUARY 13, 2024
Pictured Left to Right: Members and students of the McGill Gene Editing Laboratory at The Texas Heart Institute in Houston, Texas: Fansen Meng, PhD, Xiao Li, PhD, James Martin, MD, PhD, Rich Li, PhD (back), Maggie Lim (undergraduate student at Rice University front), Yuka Morikawa, PhD, Ann Bromley.
111 
Circulation
SEPTEMBER 10, 2024
Circulation, Ahead of Print. Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4144084-A4144084, November 12, 2024. Despite being a heart transplantation candidate, she declined revascularization and sought alternative treatments for angina, dyspnea, and daily activity limitations.
DAIC
JUNE 24, 2024
Kittleson, director of Heart Failure Research and director of Post Graduate Medical Education in Heart Failure and Transplantation, is an associate editor specializing in heart failure. Levine Early Career Clinical Investigator Award from the American Heart Association.
100 
Circulation: Heart Failure
APRIL 4, 2025
Circulation: Heart Failure, Ahead of Print. Heart failure is a global disease with significant morbidity. Heart transplant (HT) can be a lifesaving therapy for select patients with end-stage heart failure.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146823-A4146823, November 12, 2024. Heart transplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Patients without CHD were older (mean age 71.5
Circulation: Heart Failure
APRIL 14, 2025
Circulation: Heart Failure, Ahead of Print.
Circulation
MARCH 11, 2024
Circulation, Ahead of Print. Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Acute heart failure has an incidence ranging from 0.4%
45 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146828-A4146828, November 12, 2024. Heart transplantation remains a vital treatment for end-stage heart failure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need.
40 
Circulation: Heart Failure
AUGUST 1, 2024
Circulation: Heart Failure, Ahead of Print.
Circulation: Genomic and Precision Medicine
SEPTEMBER 28, 2023
Circulation: Genomic and Precision Medicine, Volume 16, Issue 5 , Page 452-461, October 1, 2023. Background:Many cardiovascular disorders propel the development of advanced heart failure that necessitates cardiac transplantation. of patients with unexplained end-stage cardiomyopathy.
Circulation: Heart Failure
DECEMBER 9, 2024
Circulation: Heart Failure, Ahead of Print.
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs.
Circulation: Heart Failure
DECEMBER 11, 2023
Circulation: Heart Failure, Ahead of Print.
Circulation: Heart Failure
JANUARY 16, 2025
Circulation: Heart Failure, Ahead of Print. BACKGROUND:Right ventricular dysfunction (RVD) is common in patients with heart failure with reduced ejection fraction, and it is associated with poor prognosis.
40 
Circulation: Heart Failure
FEBRUARY 5, 2024
Circulation: Heart Failure, Ahead of Print. BACKGROUND:Cardiac allograft vasculopathy (CAV) is the leading cause of late graft dysfunction in heart transplantation. Only patients in the moderate to high risk cluster developed the International Society for Heart and Lung Transplantation CAV 2-3 at 5 years (P=0.02).
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4134590-A4134590, November 12, 2024. The association between a lower rate of MAE and EMB persisted in the multivariate model when those with heart transplant who had EMB were compared to those without heart transplant who did not have EMB p=0.001.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4142247-A4142247, November 12, 2024. Background:Cardiac transplantation remains the single most effective treatment for end-stage heart failure. Autoradiography revealed68Ga-grazytracer accumulation in the transplanted heart. at POD 7 days; P<0.001).
40 
Circulation: Heart Failure
FEBRUARY 13, 2024
Circulation: Heart Failure, Ahead of Print. BACKGROUND:Cardiac allograft rejection is the leading cause of early graft failure and is a major focus of postheart transplant patient care.
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4144461-A4144461, November 12, 2024. Introduction:Left ventricular assist devices (LVADs) have become an increasingly common treatment option for patients with advanced heart failure, serving as either a bridge to transplantation or destination therapy.
40 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146466-A4146466, November 12, 2024. Background:Without timely intervention, pressure-overloading left ventricular (poLV) remodeling may become progressive and readily degenerate into heart failure.
Circulation
FEBRUARY 15, 2024
Circulation, Ahead of Print. BACKGROUND:Clonal hematopoiesis of indeterminate potential (CHIP), a common age-associated phenomenon, associates with increased risk of both hematological malignancy and cardiovascular disease.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146624-A4146624, November 12, 2024. Introduction:Ventricular assist devices (VADs) present great promise as both bridge-to-transplant and destination therapies for patients with end-stage heart failure.
40 Circulation
JANUARY 18, 2024
Circulation, Ahead of Print. BACKGROUND:Cardiolipin is a mitochondrial-specific phospholipid that maintains integrity of the electron transport chain (ETC) and plays a central role in myocardial ischemia/reperfusion injury. Tafazzin is an enzyme that is required for cardiolipin maturation.
Circulation: Arrhythmia and Electrophysiology
FEBRUARY 12, 2024
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:A growing number of patients with tetralogy of Fallot develop left ventricular systolic dysfunction and heart failure, in addition to right ventricular dysfunction.
DAIC
MARCH 8, 2024
suffer from heart failure , and there are approximately 400,000 heart-failure-related deaths in this country each year. Patients with heart failure often experience reduced mobility, quality of life and ability to work; the disease also represents a significant public health care burden.
98 
MIBHS
OCTOBER 31, 2024
Dilation: The chambers of the heart expand, making the walls thinner. Both forms of enlargement may compromise the heart’s ability to pump blood efficiently, leading to further complications like heart failure. What Causes an Enlarged Heart? Here are some of the most common causes: 1.
DAIC
APRIL 30, 2024
Study shows that cardiac spheroids, derived from human induced pluripotent stem cells, can be easily transported and injected into damaged areas of the heart to promote its regeneration and recovery of function. Heart attacks typically kill millions of cardiac muscle cells, leaving the heart in a weakened state.
105 
DAIC
MAY 15, 2024
The HeartMate 3 is used for both short- and long-term support in pediatric and adult patients with severe left ventricular heart failure. It can be used while waiting for a heart transplant, to help the heart recover, or as a permanent solution when a transplant isn't an option.
105 
DAIC
FEBRUARY 14, 2025
Critical limb-threatening ischemia (CLTI) represents the end stage of peripheral artery disease (PAD), when poor circulation due to blockages in the arteries causes symptoms including numbness, sores that will not heal, gangrene, and extreme pain.
Circulation: Cardiovascular Imaging
JANUARY 15, 2024
Circulation: Cardiovascular Imaging, Volume 17, Issue 1 , Page e015858, January 1, 2024. BACKGROUND:Advanced chronic kidney disease is associated with high cardiovascular risk, even after kidney transplant. years post-transplant. years post-transplant. A minority had abnormal MPI (n=58, 15%). 2.66];P=0.33).
40 Circulation: Heart Failure
FEBRUARY 1, 2024
Circulation: Heart Failure, Ahead of Print. BACKGROUND:Clinical evaluation of central venous pressure is difficult, depends on experience, and is often inaccurate in patients with chronic advanced heart failure. 0.84]) and confirmed in the validation cohort (receiver operating characteristic, 0.82 [95% CI, 0.73–0.92]).
Circulation: Heart Failure
FEBRUARY 1, 2024
Circulation: Heart Failure, Ahead of Print. BACKGROUND:In 2018, an algorithm-based allocation system for heart transplantation (HT) was implemented in France. Secondary end points included access to HT and posttransplant mortality. 4.24];P=0.03).CONCLUSIONS:Our
Circulation: Cardiovascular Imaging
APRIL 2, 2024
Circulation: Cardiovascular Imaging, Ahead of Print. BACKGROUND:In heart transplant recipients, right ventricular (RV) dysfunction may occur for a variety of reasons. Whether RV dysfunction in the stable phase after heart transplantation is associated with long-term adverse outcomes is unknown. 1.17];P=0.046).
DAIC
APRIL 15, 2024
The HeartMate II and 3 are used for both short- and long-term support in adult patients with severe left ventricular heart failure. It can be used while waiting for a heart transplant, to help the heart recover, or as a permanent solution when a transplant isn't an option.
105 
Circulation: Heart Failure
DECEMBER 10, 2024
Circulation: Heart Failure, Ahead of Print. BACKGROUND:Cardiac allograft vasculopathy (CAV) leads to impaired myocardial blood flow (MBF), increasing the risk of cardiovascular death or retransplant among heart transplantation (HT) recipients. Elevated dd-cfDNA was defined as 0.12%.RESULTS:Two 0.71%];P=0.38).
Circulation: Heart Failure
NOVEMBER 6, 2023
Circulation: Heart Failure, Ahead of Print.
Circulation: Genomic and Precision Medicine
SEPTEMBER 6, 2023
Circulation: Genomic and Precision Medicine, Volume 16, Issue 5 , Page 421-430, October 1, 2023. Background:Variants in theDMDgene, that encodes the cytoskeletal protein, dystrophin, cause a severe form of dilated cardiomyopathy (DCM) associated with high rates of heart failure, heart transplantation, and ventricular arrhythmias.
DAIC
FEBRUARY 14, 2025
Critical limb-threatening ischemia (CLTI) represents the end stage of peripheral artery disease (PAD), when poor circulation due to blockages in the arteries causes symptoms including numbness, sores that will not heal, gangrene, and extreme pain.
52 
Dr. Smith's ECG Blog
JUNE 2, 2023
J Electrocardiol, 42 (2009), pp. e5 Article Download PDF Google Scholar 3 RNW Hauer, MGPJ Cox, JA Groeneweg Impact of new electrocardiographic criteria in arrhythmogenic cardiomyopathy Front Physiol, 3 (2012), p.
96 
Cardiology Update
APRIL 9, 2024
Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). The Impella CP is a catheter-based, axial flow pump that pumps blood directly from the left ventricle into the circulation. It is able to deliver 3.5L/min
52 
Society of Thoracic Surgeons - Research
APRIL 20, 2023
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
52 
Society of Thoracic Surgeons - Research
APRIL 20, 2023
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
52 Circulation: Heart Failure
FEBRUARY 20, 2024
Circulation: Heart Failure, Ahead of Print. Background:Black heart transplant patients are at higher risk of acute rejection (AR) and death than White patients. The incidence of AR was higher in Black patients compared with White patients (43% versus 19%;P=0.002).
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content